Catalyst Calendar - February 20, 2026 (Morning)

 ## Major Catalysts Mentioned **Viatris** - Date: TBD - Why it matters: The company is seen as a deep-value pharmaceutical stock with emerging growth catalysts and strong cash generation, making it a potential investment opportunity. - Stocks affected: **$VTRS** **AMC Entertainment** - Date: TBD - Why it matters: The company is under scrutiny ahead of its Q4 earnings results, with analysts advising caution before the report due to potential disappointing outcomes. - Stocks affected: **$AMC** **AstraZeneca** - Date: TBD - Why it matters: The company's Calquence treatment has received FDA approval for CLL, which could lead to increased sales and market share in the oncology segment. - Stocks affected: **$AZN** **Nvidia** - Date: TBD - Why it matters: Nvidia is reportedly finalizing a $30 billion investment in OpenAI, which could significantly enhance its AI capabilities and market position. - Stocks affected: **$NVDA** **Opendoor Technologies** - Date: TBD - Why it matters: The company has shown progress in pivoting to a leaner business model, which may boost investor confidence and stock performance. - Stocks affected: **$OPEN** ## Earnings on Deck - **$AMC** - Reports: TBD - Key watch: Earnings results and guidance. - **$NEM** - Reports: TBD - Key watch: Production and cost metrics. ## Economic Events - **U.S. Goods Trade Deficit Report** - Date: TBD - Expected impact: Affects GDP and economic outlook. ## Regulatory & Legal - **AstraZeneca** - FDA approval for Calquence - Date: TBD ## What's NOT Dated But Worth Tracking - **US-Iran Tensions** - Watch for: Market reactions to geopolitical developments and their impact on oil prices. - **Nvidia's Investment in OpenAI** - Watch for: Future announcements regarding AI product developments and partnerships. ## Highest Conviction Catalyst - What: AstraZeneca's FDA approval for Calquence - When: TBD - Why it matters: This approval could significantly boost AstraZeneca's revenue and market share in the oncology market, potentially leading to a positive revaluation of the stock. - Trade idea: Consider buying **$AZN** as it may see a price increase following the approval.